Navigation Links
RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants
Date:6/18/2013

JERUSALEM, June 18, 2013 /PRNewswire/ --

RegeneCure announced today the start of a clinical study using the company's  proprietary AMCA Guided Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid for patients requiring dental implants.

A common problem encountered when patients have a tooth replaced with a dental implant is the lack of sufficient bone volume to house the implant. Consequently there is often a need to support the implant with a bone substitute until the natural bone regenerates. The bone substitute material, in turn, needs to be held in place by a membrane.

RegeneCure's innovative AMCA GBR membrane has important quality and safety advantages over currently-used collagen-based membranes:

The membrane is entirely synthetic, eliminating risk of contamination by pathogens present in animal-tissue-derived membranes:

The AMCA GBR membrane is strong, degrades slowly over time, giving the natural bone more time to properly regenerate;

The membrane accelerates healing by enabling excellent cell adherence, proliferation and differentiation of stem cells into the bone tissue, while preventing connective tissue from infiltrating into the healing space.

"Pre-clinical trials have shown excellent healing, including complete restoration of the bone," said Moshe Tzabari, CEO of RegeneCure, adding "Our technology is designed to improve and accelerate healing in a large variety of medical procedures."

About The Trial

A total of 32 patients suffering from insufficient bone volume for dental implant placement will be enrolled in the prospective, randomized, controlled study. One study arm, comprising 16 patients, will use RegeneCure's membrane; the other study arm, also comprising 16 patients, will use a collagen membrane.  Study participants will include non-smokers and smokers, in order to provide clinical data for potential use in both smoking and non-smoking populations.

The study will examine if RegeneCure's membrane enables a similar or better amount of lateral bone fill compared with the collagen membrane which is considered the gold standard treatment today. Each patient will be followed over a 6-month period.

The Principal Investigators are  Prof. Lior Shapira, Chairman of the Department of Periodontology at the Hadassah  Medical Center, Jerusalem, Israel and Prof. Eli Machtei, Director of the  Dept. of Oral Medicine & Periodontology at the Rambam Medical Center in Haifa, Israel.

The AMCA membrane is thin and flexible, drill-able, and easily sutured in the treated area. It is easy to use in orthopedic surgery and requires no special surgical knowledge or special preparation prior to use.

About the Market

The global dental implants market is set to almost double in value over the next six years, owing to the aging population and the availability of advanced solutions for dental implants in conjunction with oral regenerative tissue products. Global sales of dental implant systems reached more than $3.4 billion in 2012 with Europe (49%) as largest market before the United States (31%). In 2012, the global dental membrane market was over $200 million with annual growth of 5-10% to reach $300 million by 2017.

About  RegeneCure

RegeneCure Ltd. was founded in July 2010 to develop, produce and market synthetic implants for bone reconstruction and fracture fusion for the orthopedic, dental and aesthetic fields. AMCA Membrane Implant technology is protected by worldwide patents. The company submitted a 510(k) application to the FDA in April 2012 for an initial trauma indication. The privately owned company has manufacturing facility meeting the high production standards required by European and United States authorities. In 2012, the company received ISO 13485:2003 certification.

For more information visit  http://www.regenecure.co.il or contact: Dr. Harry Langbeheim, VP Business Development, harry@regenecure.co.il, Tel: +972-2-5401013


'/>"/>
SOURCE RegeneCure Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management
2. Lab course that starts with students own ideas wins Science magazine prize
3. Management Matters Series Starts with “Lab Budgeting 101”
4. Week One of All Things Medical Auction Event Starts Monday, March 11, 2013 Conducted by IpAuctions™, Inc.
5. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
6. Positive Clinical Study Results for BSPs HyperQ Technology
7. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
8. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
9. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
10. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
11. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
Breaking Biology News(10 mins):